Literature DB >> 31402328

Role of Beta-blockers in Cardiovascular Disease in 2019.

Juan Martínez-Milla1, Sergio Raposeiras-Roubín2, Domingo A Pascual-Figal3, Borja Ibáñez4.   

Abstract

Beta-blockers are the cornerstone of treatment for various cardiovascular conditions. Although their effects have classically been considered to be driven by their antagonistic and competitive action on beta-adrenergic receptors, nowadays it is known that their effect goes beyond that of mere competition with catecholamines on these receptors. Beta-blockers were discovered as antianginal drugs in the 1960s and are currently widely used in heart failure, arrhythmias, and ischemic heart disease. In this article, we review the evidence for the beneficial effects of beta-blockers in these conditions, as well as the current recommendations in clinical practice guidelines for their use. Surprisingly, despite having been prescribed for more than 4 decades, new, previously unnoticed mechanisms of action on cellular compartments are still being discovered, which continues to open up new horizons for their use. All in all, beta-blockers are one of the most fascinating drug groups in our therapeutic armamentarium.
Copyright © 2019 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Acute myocardial infarction; Beta-blockers; Bloqueadores beta; Heart failure; Infarto agudo de miocardio; Insuficiencia cardiaca

Mesh:

Substances:

Year:  2019        PMID: 31402328     DOI: 10.1016/j.rec.2019.04.014

Source DB:  PubMed          Journal:  Rev Esp Cardiol (Engl Ed)        ISSN: 1885-5857


  6 in total

1.  Beta-Blocker-Related Atrioventricular Conduction Disorders-A Single Tertiary Referral Center Experience.

Authors:  Dragoș Traian Marius Marcu; Cristina Andreea Adam; Dan-Mihai Dorobanțu; Delia Lidia Șalaru; Radu Andy Sascău; Mircea Ovanez Balasanian; Liviu Macovei; Cătălina Arsenescu-Georgescu; Cristian Stătescu
Journal:  Medicina (Kaunas)       Date:  2022-02-20       Impact factor: 2.430

2.  Population-based pattern of medication use and prevalence of polypharmacy among patients with cardiovascular diseases: results of the Pars cohort study from Iran.

Authors:  Ali Ardekani; Pooran Mohsenzadeh; Hossein Poustchi; Zahra Mohammadi; Seyed Reza Abdipour Mehrian; Hamed Bazrafshan Drissi; Zahra Rahimian; Erfan Taherifard; Ali Nabavizadeh; Alireza Kamalipour; Bita Mesgarpour; Fatemeh Malekzadeh; Hossein Molavi Vardanjani
Journal:  BMC Cardiovasc Disord       Date:  2022-10-06       Impact factor: 2.174

Review 3.  Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases.

Authors:  Fangyu Yang; Jianjiang Xue; Guixue Wang; Qizhi Diao
Journal:  Front Pharmacol       Date:  2022-09-12       Impact factor: 5.988

4.  Metoprolol blunts the time-dependent progression of infarct size.

Authors:  Manuel Lobo-Gonzalez; Carlos Galán-Arriola; Xavier Rossello; Maribel González-Del-Hoyo; Jean Paul Vilchez; María I Higuero-Verdejo; Jose M García-Ruiz; Gonzalo J López-Martín; Javier Sánchez-González; Eduardo Oliver; Gonzalo Pizarro; Valentin Fuster; Borja Ibanez
Journal:  Basic Res Cardiol       Date:  2020-08-03       Impact factor: 17.165

5.  Metoprolol in Critically Ill Patients With COVID-19.

Authors:  Agustín Clemente-Moragón; Juan Martínez-Milla; Eduardo Oliver; Arnoldo Santos; Javier Flandes; Iker Fernández; Lorena Rodríguez-González; Cristina Serrano Del Castillo; Ana-María Ioan; María López-Álvarez; Sandra Gómez-Talavera; Carlos Galán-Arriola; Valentín Fuster; César Pérez-Calvo; Borja Ibáñez
Journal:  J Am Coll Cardiol       Date:  2021-09-07       Impact factor: 24.094

6.  Temporal haemodynamic changes after bisoprolol treatment in patients with uncontrolled hypertension.

Authors:  Weiwei Zeng; Brian Tomlinson
Journal:  Ann Transl Med       Date:  2021-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.